Novo's weight-loss drug shows improvement in fatty liver disease in late-stage trial

(Reuters) -Novo Nordisk said on Friday its weight-loss drug met the main goals of a late-stage trial in patients with a type of fatty liver disease by helping reduce scarring of the organ while not worsening inflammation. The closely watched trial studied the 2.4 milligram dose of semaglutide for the treatment of a condition called metabolic dysfunction-associated steatotic liver disease.